DOCSLIB.ORG

Contribution of Endo- and Exopeptidases to Formation of Non-Protein N During Ensiling of Alfalfa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Contribution of Endo- and Exopeptidases to Formation of Non-Protein N During Ensiling of Alfalfa Contribution of endo- and exopeptidases to formation of non-protein N during ensiling of alfalfa Dr. Xusheng Guo,1 W. Cheng,1 L. Tao,2 Yu Zhu,2 F.Y. Yang 2 & H. Zhou2 1.School of Life Science, Lanzhou University 1. International Centre for Tibetan Plateau Ecosystem Management (ICTPEM), Lanzhou University 2. Institute of Grassland Science, China Agricultural University Hämeenlinna, Finland 2-4 July 2012 Introduction Alfalfa (Medicago Sativa L.) is well known for its high nutritive value However, after ensiling: N use efficiency Extensive ppyroteolysis Reduce True protein NPN(Peptide, FAA, NH3-N etc.) Silage DM intake (44-87% of Total N; Muck, 1987) Silage Fermentation Proteolysis in ensiled forage mainly results from plant proteases (Ohshima and McDonald, 1978; McKersie, 1981; Heron et al., 1988). Proteases (peptidases) are divided into 2 classes (NC-IUBMB, 1992): Exopeptidase Endopeptidase Objectives Proteases (peptidases, E.C.3.4） Endopeptidases Exopeptidases ？！ Ser ine pep tidase (E .C .3 .4 .21) Aminopeptidase (EC 3.4.11) Carboxypeptidase (EC 3.4.16) Cysteine peptidase (E.C.3.4.22) Dipeptidase (EC 3.4.13) Aspartic Peptidase (E.C.3.4.23) Dipeptidyl-peptidase (EC 3.4.14) Metallopeptidase (E.C.3.4.24) Tripeptidyl-peptidase (EC 3.4.14) Peptidyl-dipeptidase (EC 3.4.15) Aims of our research were: 1. To clarify the classes of exo- and endopeptidases that are involved in proteolysis within ensiled alfalfa. 2. To determine the contribution of these peptidases to the formation of different NPN compounds (peptide-N, FAA-N, and NH3-N) during ensiling Materials and Methods Trial 1: Determination of Peptidase Classes in Fresh Alfalfa Crude Enzymes Extraction (Feller et al ., 1977 ) Crude enzyme extract 5g ground in Desalted at 4 liquid N Centrifugation Ԩ in Sephadex 4Ԩ, 20, 000 20ml, pH7.5, G-25 columns 25 ml Tris-HCl r/min for 10 min Residual Crude Specific Incubation Enzyme Incubate at Measure ＋ peptidase Fischer enzyme ＋ inhibitors 20 C for 0.5 h substrates 37Ԩ for 1 h etal.,1998 activities For each of the exo- Compared to control (Without and endopeptidase inhibitor) Materials and Methods Table 1. Endopeptidases and specific inhibitors Table 2. Exopeptidases and specific inhibitors Endo- Inhibitors Concentration Exopeptidase Inhibitors Concentration peptidase used used Aminopeptidase Serine PMSF* 5 mM Bestatin 0.05 mM Carboxy-peptidase PCI* 0.825 μM Pepstatin A 1mM1 mM Aspartate 1,10- Dipeptidase 10 mM phenanthroline 1,10- 10 mM Dipeptidyl-peptidase Driprotin A 0.5 mM Metallo phenanthroline TiTripep tidltidyl-peptidase Bu ta bin dide 0. 025 m M dipeptide 0.25 mM Cysteine E-64* 1 mM Peptidyl-dipeptidase Phe-Arg *PMSF, phenylmethanesulfonyl fluoride. *E-64, L-trans-epoxysuccinyl-leucylamide- (4-guanidino)-butane. *PCI, potato carboxypeptidase inhibitor Materials and Methods Trial 2: Determination of concentration of each inhibitor required for different peptidases Table 3. Inhibitor concentrations designed for each of the endo- and exopeptidase inhibitors The experimental method is same as Trial 1 Materials and Methods Trial 3: Determination of contribution of endo- and exopeptidases to formation of NPN during ensiling of alfalfa Aqueous Extracts of Whole-crop Alfalfa were fermented to imitate the fermentation of ensiled alfalfa forage Fermented at 30Ԩ Aqueous ＋ Specific Analysis of Extracts inhibitors NPN and its 1, 2, 3, 5, 7, 14, and 21 d constitutes Endopeptidase Exopeptidase Concentration used Concentration used inhibitor treatments inhibitor treatments Control - Control - PMSF (A) 5 mM Bestatin(A) 0.1 mM Pepstatin A (B) 0.1 mM PCI (B) 0.413 mM 1,10-phenanthroline (C) 5 mM 1,10-phenanthroline (C) 50 mM E-64 (D) 0.1 mM DiDriprot in A (D) 2 mM A+B+C+D - Butabindide (E) 0.5 mM A+B+C+D+E - Results and discussion Guo et al ., Anim Feed Sci Technol .168 (2011) ,42 -50; Tao et al . J Dairy Sci . 94 (2011) ,3928 -3935. 1. Identification on classes of exo- and endopeptidases in alfalfa Table 1. Changes in proteolytic activity of exopeptidases in crude enzyme extract of alfalfa after peptidase inhibition treatments Table 2. Changes in proteolytic activity of endopeptidases in crude enzyme extract of alfalfa after peptidase inhibition treatment 1Proteolytic activity was express as absorbance of the incubation samples at 570nm directly and the proteolytic activity in the fresh alfalfa extract was considered as 100 percent. Results and discussion 2. Contribution of exopeptidases to formation of NPN during fermentation of alfalfa extract B C A Carboxy- and dipeptidases TN TN control gg control Control -N mg/g 3 NH tide-N, mg/g tide-N, mg/g TN mino acid-N, mg/ pp AA Pe Tripeptidyl-peptidase Day of fermentation Day of fermentation Day of fermentation Figure 1. Concentrations of NH3-N (A), AA-N (B), and peptide-N (C) in the fermented alfalfa extract treated with different specific enzyme inhibitors of exopeptidases Table 3. NPN, Peptide-N, AA-N and NH3-N contents (mg/g total N) in fresh and fermented alfalfa extracts with different specific enzyme inhibitors (exopeptidases) for periods of up to 14 days Inhibitor classes Inhibitor NH3-N AA-N Peptide-N NPN Fresh alfalfa extracts <0.001 28.0 209.0 237.0 Fermented extracts Control - 26.0a 321.1c 273.4cd 620.5a Bestatin Aminopeptidase 8.4b 273.7d 317.2b 589.3a PCI* Carboxypeptidase 12.2b 236.3e 291.9bc 540.4b 1,10-phenanthroline Dipeptidase 0.0c 219.8e 258.1d 472.9c DriprotinA Dipeptidyl-peptidase 28.6a 346.9b 211.5e 587.0a Butabindide Tripeptidyl-peptidase 24. 3a 381. 6a 133. 0f 538. 9b Combined inhibitors Five of the peptidases 0.0c 109.8f 350.5a 460.3c SEM 2.40 77.2 37.4 62.4 a-fMeans within a column with different suppperscripts differ ( P < 0.05). * PCI, potato carboxypeptidase inhibitor. SEM, standard error of the mean. Five exopeptidase inhibitors could reduce reduce the NPN content in the fermented alfalfa extract to about 42% of that in the control after 14 d of fermentation 3. Contribution of endopeptidases to formation of NPN duringgg ensiling of alfalfa Control Control Metallo peptidase Control Control Peptide-N Aspartate peptidase Day of fermentation Day of fermentation Figure 1. Concentrations of NH3-N (A), free amino acid-N (B), and peptide-N (C) in the fermented alfalfa extract treated with different specific enzyme inhibitors of endopeptidases (mg/g TN) Table 4. NPN, Peptide-N, AA-N and NH3-N contents (mg/g total N) in fresh and fermented alfalfa extracts with different specific enzyme inhibitors (endopeptidases) for periods of up to 14 days a-f Means within a column with different superscripts differ (P < 0.05). *PMSF, phenylmethanesulfonyl fluoride. SEM, standard error of the mean. Four inhibitors reduced the total NPN content in fermented alfalfa extract to about 44% of that in the control after 14 d of fermentation. Conclusions Five exo- and 4 endopeptidases were presented in alfalfa leaves Dipeptidase, carboxypeptidase and tripeptidyl-peptidase were the principal exopepdidases contributing to the proteolysis in ensiled alfalfa Metallo and cysteine peptidases are thought to be the principle endopppeptidases for p rotein deg radation during ensiling of alfalfa Exo- and endopeptidase were comparable in contributing to formation of NPN during ensiling of alfalfa . Thank you very much for your attention ! .
Load more

Recommended publications
  • Molecular Markers of Serine Protease Evolution
    The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages.
    [Show full text]
  • Processing of Antigenic Peptides by Aminopeptidases
    June 2004 Biol. Pharm. Bull. 27(6) 777—780 (2004) 777 Current Topics Aminopeptidases in Health and Disease Processing of Antigenic Peptides by Aminopeptidases Akira HATTORI* and Masafumi TSUJIMOTO Laboratory of Cellular Biochemistry, RIKEN; 2–1 Hirosawa, Wako, Saitama 351–0198, Japan. Received January 7, 2004 Antigenic peptides presented to major histocompatibility complex (MHC) class I molecules are generated in the cytosol during degradation of cellular proteins by the ubiquitin-proteasome proteolytic pathway. Proteasome can generate N-extended precursors as well as final epitopes, and then the precursors are processed to mature epitopes by aminopeptidases. Both cytosolic peptidases (i.e. puromycin-sensitive aminopeptidase, bleomycin hy- drolase and interferon-g-inducible leucine aminopeptidase) and recently identified metallo-aminopeptidase lo- cated in the endoplasmic reticulum (i.e. adipocyte-derived leucine aminopeptidase/endoplasmic reticulum aminopeptidase 1 and leukocyte-derived arginine aminopeptidase) can generate final epitopes from precursor peptides. Some of these aminopeptidases are also considered to destroy certain antigenic peptides to limit the antigen presentation. Taken together, it is getting evident that aminopeptidases located in the cytosol and the lumen of endoplasmic reticulum play important roles in the generation of antigenic peptides presented to MHC class I molecules. Key words aminopeptidase; antigen processing; major histocompatibility complex (MHC) class I; antigen presentation; protea- some; protein degradation
    [Show full text]
  • Catalytic Properties and Inhibition of Proline-Specific Dipeptidyl Peptidases II, IV and VII
    UC Berkeley UC Berkeley Previously Published Works Title Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII Permalink https://escholarship.org/uc/item/4nf146zf Journal Biochemical Journal, 371 ISSN 0264-6021 Authors Leiting, B Pryor, K D Wu, J K et al. Publication Date 2003-04-01 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Biochem. J. (2003) 371, 525–532 (Printed in Great Britain) 525 Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII Barbara LEITING*1, KellyAnn D. PRYOR*, Joseph K. WU*, Frank MARSILIO*, Reshma A. PATEL*, Charles S. CRAIK†, Jonathan A. ELLMAN‡, Richard T. CUMMINGS* and Nancy A. THORNBERRY* *Department of Metabolic Disorders, Merck Research Laboratories, Mail code RY50G-236, P.O. Box 2000, Rahway, NJ 07065, U.S.A., †Department of Pharmaceutical Chemistry, University of California, 513 Parnassus Avenue, San Francisco, CA 94143-0446, U.S.A., and ‡Department of Chemistry, University of California, Berkeley, CA 94720, U.S.A. There is currently intense interest in the emerging group of strates and inhibitors for these enzymes, a complete biochemical proline-specific dipeptidases, and their roles in the regulation profile of these enzymes was obtained. The pH profiles, substrate of biological processes. Dipeptidyl peptidase IV (DPP-IV) is specificities as determined by positional scanning, Michaelis– involved in glucose metabolism by contributing to the regulation Menten constants and inhibition profiles for DPP-VII and DPP- of glucagon family peptides and has emerged as a potential target II were shown to be virtually identical, strongly supporting the for the treatment of metabolic diseases.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Enzymatic Hydrolysis and Peptide Mapping of Potato Pulp Protein
    Enzymatic Hydrolysis and Peptide Mapping of Potato Pulp Protein Von der Naturwissenschaftlichen Fakultät der Universität Hannover zur Erlangung des Grades Doktorin der Naturwissenschaften Dr. rer. nat. genehmigte Dissertation von Chulaporn Kamnerdpetch, M.Sc. geboren in Bangkok, Thailand Hannover 2006 Hauptreferent Prof. Dr. Thomas Scheper Institut für Technische Chemie Universität Hannover Koreferent Prof. Dr. Bernd Hitzmann Institut für Technische Chemie Universität Hannover Tag der Promotion 29. Mai 2006 Erklärung Ich versichere, dass ich diese Dissertation selbstständig und nur unter Verwendung der angegebenen Hilfsmittel und Quellen durchgeführt habe. Diese Arbeit wurde nicht als Diplomarbeit oder ähnliche Prüfungsarbeit verwendet. Chulaporn Kamnerdpetch Hannover, den 29. Mai 2006 ACKNOWLEDGEMENTS This thesis is the result of my four years research work whereby I have been accompanied and supported by many people. It is a pleasant aspect that I have now the opportunity to express my sincere gratitude for all of them who made this thesis possible. The first person I would like to thank is my supervisor Prof. Dr. Thomas Scheper for giving me the opportunity to take part on the doctoral program at the Institut für Technische Chemie der Universität Hannover. I appreciate very much for his enthusiastic and enthusing support. He gave me an encourage independent thinking and the freedom to try out my ways. I would like to thank to Prof. Dr. Bernd Hitzmann for his kindness acceptance as my co-referee. I wish to express my thank to Dr. Cornelia Kasper for preparing my publication and proof reading. It is a great pleasure for me to thank Dr. Pichai Namparkai for proof reading as well.
    [Show full text]
  • JASON MARC GOLDSTEIN the Isolation, Characterization
    JASON MARC GOLDSTEIN The Isolation, Characterization and Cloning of Three Novel Peptidases From Streptoccocus gordonii: Their Potential Roles in Subacute Bacterial Endocarditis (Under the Direction of JAMES TRAVIS) Streptococcus gordonii is generally considered a benign inhabitant of the oral microflora yet is a primary etiological agent in the development of subacute bacterial endocarditis (SBE), an inflammatory state that propagates thrombus formation and tissue damage on the surface of heart valves. Colonization and adherence mechanisms have been identified, yet factors necessary to sustain growth remain unidentified. Strain FSS2 produced three extracellular aminopeptidase activities during growth in neutral pH- controlled batch cultures. The first included a serine-class dipeptidyl-aminopeptidase, an x-Pro DPP (Sg-xPDPP) found as an 85 kDa monomer by SDS-PAGE while appearing as a homodimer under native conditions. Kinetic studies indicated a unique and stringent x- Pro specificity comparable to the DPPIV/CD26 and lactococcal x-Pro DPP families. Isolation of the full-length gene uncovered a 759-amino acid polypeptide with a mass of 87,115 Da and theoretical pI of 5.6. Significant homology was found with PepX gene family members from Lactobacillus ssp. and Lactococcus ssp., and putative streptococcal x-Pro DPPs. The second activity was a putative serine-class arginine aminopeptidase (Sg- RAP) with some cysteine-class characteristics. It was found as a protein monomer of 70 kDa under denaturing conditions. Nested PCR cloning enabled the isolation of a 324 bp- long DNA fragment encoding the protein’s 108 amino acid N-terminus. Culture activity profiles and N-terminal sequence analysis indicated the release of this protein from the cell surface.
    [Show full text]
  • Genetic Polymorphism of the Angiotensin-Converting Enzyme (ACE) in Asthmatic Patients
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector RESPIRATORY MEDICINE (1998) 92, 1305-1310 Original Articles Genetic polymorphism of the angiotensin-converting enzyme (ACE) in asthmatic patients H. TOMITA, S. SATO, R. MATSUDA, N. OGISU, T. MORI, T. NIIMI AND S. SHIMIZU 2nd Department of Intemal Medicine, Nagoya City University Medical School, Nagoya, Japan Angiotensin-converting enzyme (ACE) inactivates bradykinin, substance P and neurokinin A, which are believed to play important roles in the pathogenesis of asthma, especially in neurogenic inflammation. It has recently been shown that an insertion (1)ldeletion (D) polymorphism in the ACE gene accounts for variation in serum ACE levels. There are thus three genotypes (insertion homozygote, II; deletion homozygote, DD; heterozygotes, DI). The serum ACE level with the DD type is reported to be about double that of the II type and intermediate in the DI case. In the present study, we examined whether asthma is linked with this ACE gene polymorphism. Seventy-one patients with asthma (27 males and 44 females) and 142 sex- and age-matched healthy controls were determined for their genotype by the polymerase chain reaction (PCR) method. Twenty-five asthmatics demonstrated the II type (352%) 37 the DI type (52.1%), and nine the DD type (12.7%). There were no significant differences in the distributions of genotypes and serum ACE levels between healthy controls and patients. No significant differences were evident in serum IgE levels, age at onset, proportion of atopic type patients and severity of asthma among the three genotypes.
    [Show full text]
  • B Number Gene Name Mrna Intensity Mrna
    sample) total list predicted B number Gene name assignment mRNA present mRNA intensity Gene description Protein detected - Membrane protein membrane sample detected (total list) Proteins detected - Functional category # of tryptic peptides # of tryptic peptides # of tryptic peptides detected (membrane b0002 thrA 13624 P 39 P 18 P(m) 2 aspartokinase I, homoserine dehydrogenase I Metabolism of small molecules b0003 thrB 6781 P 9 P 3 0 homoserine kinase Metabolism of small molecules b0004 thrC 15039 P 18 P 10 0 threonine synthase Metabolism of small molecules b0008 talB 20561 P 20 P 13 0 transaldolase B Metabolism of small molecules chaperone Hsp70; DNA biosynthesis; autoregulated heat shock b0014 dnaK 13283 P 32 P 23 0 proteins Cell processes b0015 dnaJ 4492 P 13 P 4 P(m) 1 chaperone with DnaK; heat shock protein Cell processes b0029 lytB 1331 P 16 P 2 0 control of stringent response; involved in penicillin tolerance Global functions b0032 carA 9312 P 14 P 8 0 carbamoyl-phosphate synthetase, glutamine (small) subunit Metabolism of small molecules b0033 carB 7656 P 48 P 17 0 carbamoyl-phosphate synthase large subunit Metabolism of small molecules b0048 folA 1588 P 7 P 1 0 dihydrofolate reductase type I; trimethoprim resistance Metabolism of small molecules peptidyl-prolyl cis-trans isomerase (PPIase), involved in maturation of b0053 surA 3825 P 19 P 4 P(m) 1 GenProt outer membrane proteins (1st module) Cell processes b0054 imp 2737 P 42 P 5 P(m) 5 GenProt organic solvent tolerance Cell processes b0071 leuD 4770 P 10 P 9 0 isopropylmalate
    [Show full text]
  • Table 6. Putative Genes Involved in the Utilization of Carbohydrates in G
    Table 6. Putative genes involved in the utilization of carbohydrates in G. thermodenitrificans NG80-2 genome Carbohydrates* Enzymes Gene ID Glycerol Glycerol Kinase GT1216 Glycerol-3-phosphate dehydrogenase, aerobic GT2089 NAD(P)H-dependent glycerol-3-phosphate dehydrogenase GT2153 Enolase GT3003 2,3-bisphosphoglycerate-independentphosphoglycerate mutase GT3004 Triosephosphate isomerase GT3005 3-phosphoglycerate kinase GT3006 Glyceraldehyde-3-phosphate dehydrogenase GT3007 Phosphoglycerate mutase GT1326 Pyruvate kinase GT2663 L-Arabinose L-arabinose isomerase GT1795 L-ribulokinase GT1796 L-ribulose 5-phosphate 4-epimerase GT1797 D-Ribose Ribokinase GT3174 Transketolase GT1187 Ribose 5-phosphate epimerase GT3316 D-Xylose Xylose kinase GT1756 Xylose isomerase GT1757 D-Galactose Galactokinase GT2086 Galactose-1-phosphate uridyltransferase GT2084 UDP-glucose 4-epimerase GT2085 Carbohydrates* Enzymes Gene ID D-Fructose 1-phosphofructokinase GT1727 Fructose-1,6-bisphosphate aldolase GT1805 Fructose-1,6-bisphosphate aldolase type II GT3331 Triosephosphate isomerase GT3005 D-Mannose Mannnose-6 phospate isomelase GT3398 6-phospho-1-fructokinase GT2664 D-Mannitol Mannitol-1-phosphate dehydrogenase GT1844 N-Acetylglucosamine N-acetylglucosamine-6-phosphate deacetylase GT2205 N-acetylglucosamine-6-phosphate isomerase GT2204 D-Maltose Alpha-1,4-glucosidase GT0528, GT1643 Sucrose Sucrose phosphorylase GT3215 D-Trehalose Alpha-glucosidase GT1643 Glucose kinase GT2381 Inositol Myo-inositol catabolism protein iolC;5-dehydro-2- GT1807 deoxygluconokinase
    [Show full text]
  • High-Resolution Mass Spectrometry-Based Approaches for the Detection and Quantification of Peptidase Activity in Plasma
    molecules Article High-Resolution Mass Spectrometry-Based Approaches for the Detection and Quantification of Peptidase Activity in Plasma Elisa Maffioli 1,2 , Zhenze Jiang 3, Simona Nonnis 1,2 , Armando Negri 1,2, Valentina Romeo 1, Christopher B. Lietz 3, Vivian Hook 3,4, Giuseppe Ristagno 5, Giuseppe Baselli 6, Erik B. Kistler 7,8 , Federico Aletti 9, Anthony J. O’Donoghue 3,* and Gabriella Tedeschi 1,2,* 1 Department of Veterinary Medicine, University of Milano, 20133 Milano, Italy; elisa.maffi[email protected] (E.M.); [email protected] (S.N.); [email protected] (A.N.); [email protected] (V.R.) 2 Centre for Nanostructured Materials and Interfaces (CIMAINA), University of Milano, 20133 Milano, Italy 3 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA; [email protected] (Z.J.); [email protected] (C.B.L.); [email protected] (V.H.) 4 Department of Neurosciences, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA 5 Department of Pathophysiology and Transplantation, University of Milan, 20133 Milan, Italy; [email protected] 6 Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, 20133 Milan, Italy; [email protected] 7 Department of Anesthesiology & Critical Care, University of California San Diego, La Jolla, CA 92093, USA; [email protected] 8 Department of Anesthesiology & Critical Care, VA San Diego HealthCare System, San Diego, CA 92161, USA 9 Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA; [email protected] * Correspondence: [email protected] (A.J.O.); [email protected] (G.T.); Tel.: +1-8585345360 (A.J.O.); +39-02-50318127 (G.T.) Academic Editor: Paolo Iadarola Received: 28 July 2020; Accepted: 4 September 2020; Published: 6 September 2020 Abstract: Proteomic technologies have identified 234 peptidases in plasma but little quantitative information about the proteolytic activity has been uncovered.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier Et Al
    US 200601 10747A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier et al. (43) Pub. Date: May 25, 2006 (54) PROCESS FOR IMPROVED PROTEIN (60) Provisional application No. 60/591489, filed on Jul. EXPRESSION BY STRAIN ENGINEERING 26, 2004. (75) Inventors: Thomas M. Ramseier, Poway, CA Publication Classification (US); Hongfan Jin, San Diego, CA (51) Int. Cl. (US); Charles H. Squires, Poway, CA CI2O I/68 (2006.01) (US) GOIN 33/53 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: (52) U.S. Cl. ................................ 435/6: 435/7.1; 435/471 KING & SPALDING LLP 118O PEACHTREE STREET (57) ABSTRACT ATLANTA, GA 30309 (US) This invention is a process for improving the production levels of recombinant proteins or peptides or improving the (73) Assignee: Dow Global Technologies Inc., Midland, level of active recombinant proteins or peptides expressed in MI (US) host cells. The invention is a process of comparing two genetic profiles of a cell that expresses a recombinant (21) Appl. No.: 11/189,375 protein and modifying the cell to change the expression of a gene product that is upregulated in response to the recom (22) Filed: Jul. 26, 2005 binant protein expression. The process can improve protein production or can improve protein quality, for example, by Related U.S. Application Data increasing solubility of a recombinant protein. Patent Application Publication May 25, 2006 Sheet 1 of 15 US 2006/0110747 A1 Figure 1 09 010909070£020\,0 10°0 Patent Application Publication May 25, 2006 Sheet 2 of 15 US 2006/0110747 A1 Figure 2 Ester sers Custer || || || || || HH-I-H 1 H4 s a cisiers TT closers | | | | | | Ya S T RXFO 1961.
    [Show full text]
  • Proteasome Inhibitors: from Research Tools to Drug Candidates
    Chemistry & Biology 8 (2001) 739^758 www.elsevier.com/locate/chembiol Review Proteasome inhibitors: from research tools to drug candidates Alexei F. Kisselev*, Alfred L. Goldberg Department of Cell Biology, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115, USA Received 13 December 2000; revisions requested 29 March 2001; revisions received 12 June 2001; accepted 19 June 2001 First published online 12 July 2001 Abstract The 26S proteasome is a 2.4 MDa multifunctional ATP- inhibitors are now in clinical trials for treatment of multiple dependent proteolytic complex, which degrades the majority of cancers and stroke. ß 2001 Elsevier Science Ltd. All rights re- cellular polypeptides by an unusual enzyme mechanism. Several served. groups of proteasome inhibitors have been developed and are now widely used as research tools to study the role of the ubiquitin^ Keywords: Proteasome inhibitor; proteasome pathway in various cellular processes, and two Ubiquitin^proteasome pathway; Drug candidate 1. Introduction of cyclins and inhibitors of cyclin-dependent kinases [7], while degradation of transcriptional regulators, such as The ubiquitin^proteasome pathway is the major proteo- c-Jun, E2F-1 and L-catenin (see [8] for review) is essential lytic system in the cytosol and nucleus of all eukaryotic for the regulation of cell growth and gene expression. cells. This ATP-dependent pathway was discovered more Similarly, degradation by the proteasome of activated pro- than 20 years ago [1,2], but the involvement of the pro- tein kinases, e.g. src and protein kinase C [9,10], is critical teasome particle was demonstrated only in the late 1980s for the termination of certain signal transduction cascades.
    [Show full text]